Vanda Pharmaceuticals Inc.

VNDA

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001806596-26-000002
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Moran Kevin Patrick (CFO)

Summary

Type

Sell

Net shares

-42,442

% of shares

-9.34%

Amount (USD)

$350,821

Insider confidence score

40.0 out of 100

Positive

  • Tax withholding obligation

Negative

  • Large tax withholding sell (≥1% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-42,442.0

Price per Share

$8.27

Amount (USD)

$350,821.33

Acquired/Disposed

Disposed

Shares Owned Before

453,822.0

Shares Owned After

411,380.0

Filing's footnotes

1. Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.